Literature DB >> 11752062

Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease.

Y Itoh1, T Esaki, M Cook, P Qasba, K Shimoji, J Alroy, R O Brady, L Sokoloff, D F Moore.   

Abstract

Fabry disease is an X-linked lysosomal disorder characterized by deficient alpha-galactosidase A activity and intracellular accumulations of glycosphingolipids, mainly globotriaosylceramide (Gb3). Clinically, patients occasionally present CNS dysfunction. To examine the pathophysiology underlying brain dysfunction, we examined glucose utilization (CMR(glc)) and cerebral blood flow (CBF) globally and locally in 18 brain structures in the alpha-galactosidase A gene knockout mouse. Global CMR(glc) was statistically significantly reduced by 22% in Fabry mice (p < 0.01). All 18 structures showed decreases in local CMR(glc) ranging from 14% to 33%. The decreases in all structures of the diencephalon, caudate-putamen, brain stem, and cerebellar cortex were statistically significant (p < 0.05). Global cerebral blood flow (CBF) and local CBF measured in the same 18 structures were lower in Fabry mice than in control mice, but none statistically significantly. Histological examination of brain revealed no cerebral infarcts but abundant Gb3 deposits in the walls of the cerebral vessels with neuronal deposits localized to the medulla oblongata. These results indicate an impairment in cerebral energy metabolism in the Fabry mice, but one not necessarily due to circulatory insufficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11752062     DOI: 10.1046/j.1471-4159.2001.00669.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  11 in total

1.  Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation.

Authors:  Mei Qin; Julia Kang; Carolyn Beebe Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease.

Authors:  R J Kalliokoski; I Kantola; K K Kalliokoski; E Engblom; J Sundell; J C Hannukainen; T Janatuinen; O T Raitakari; J Knuuti; M Penttinen; J Viikari; P Nuutila
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

3.  Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.

Authors:  T Heare; N J Alp; D A Priestman; A B Kulkarni; P Qasba; T D Butters; R A Dwek; K Clarke; K M Channon; F M Platt
Journal:  J Inherit Metab Dis       Date:  2006-12-25       Impact factor: 4.982

4.  Cerebral hemodynamics and endothelial function in patients with Fabry disease.

Authors:  Tomás Segura; Oscar Ayo-Martín; Isabel Gómez-Fernandez; Carolina Andrés; Miguel A Barba; José Vivancos
Journal:  BMC Neurol       Date:  2013-11-11       Impact factor: 2.474

Review 5.  Cerebral Small Vessel Disease (CSVD) - Lessons From the Animal Models.

Authors:  Muzaimi Mustapha; Che Mohd Nasril Che Mohd Nassir; Niferiti Aminuddin; Amanina Ahmad Safri; Mazira Mohamad Ghazali
Journal:  Front Physiol       Date:  2019-10-24       Impact factor: 4.566

Review 6.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications.

Authors:  Frank Weidemann; Maria D Sanchez-Niño; Juan Politei; João-Paulo Oliveira; Christoph Wanner; David G Warnock; Alberto Ortiz
Journal:  Orphanet J Rare Dis       Date:  2013-08-06       Impact factor: 4.123

Review 7.  Cerebral small vessel disease: Capillary pathways to stroke and cognitive decline.

Authors:  Leif Østergaard; Thorbjørn S Engedal; Fiona Moreton; Mikkel B Hansen; Joanna M Wardlaw; Turgay Dalkara; Hugh S Markus; Keith W Muir
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-14       Impact factor: 6.200

8.  Altered Gene Expression in Prefrontal Cortex of a Fabry Disease Mouse Model.

Authors:  Kai K Kummer; Theodora Kalpachidou; Miodrag Mitrić; Michiel Langeslag; Michaela Kress
Journal:  Front Mol Neurosci       Date:  2018-06-25       Impact factor: 5.639

Review 9.  Cerebral Small Vessel Disease.

Authors:  Qian Li; Yang Yang; Cesar Reis; Tao Tao; Wanwei Li; Xiaogang Li; John H Zhang
Journal:  Cell Transplant       Date:  2018-09-25       Impact factor: 4.064

10.  Inhibition of Mitochondrial Complex I Impairs Release of α-Galactosidase by Jurkat Cells.

Authors:  Jonathan R A Lambert; Steven J Howe; Ahad A Rahim; Derek G Burke; Simon J R Heales
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.